Body weight
The GLP-1 line: what the numbers move, and what they leave alone
A 2024 meta-analysis of nine randomised trials pooled 11 641 people on once-weekly semaglutide and 10 479 on placebo. Body weight fell 11.49 percent against placebo, waist 9.06 centimetres, and nausea was four times more likely. Serious adverse events were not significantly different, but stopping for adverse events was about twice as likely (odds ratio 2.22).